For the first time, Anthropic's independent oversight body controls the majority of the company's board. The Long-Term Benefit Trust (LTBT) - a group of directors with no financial stake in Anthropic, designed to keep the company accountable to its stated mission - has appointed Novartis CEO Vas Narasimhan as a new board member, pushing Trust-appointed directors past the 50% threshold.
The LTBT's structure is unusual by Silicon Valley standards. Unlike most startup boards, which are dominated by founders and investors with equity at stake, the LTBT exists specifically to represent the public interest. Its mandate is to ensure Anthropic's financial success doesn't drift from its core goal of developing AI safely. With Narasimhan's addition, Trust-appointed directors now sit alongside Anthropic co-founders Dario and Daniela Amodei, and outside directors Yasmin Razavi, Jay Kreps, Reed Hastings, and Chris Liddell.
Narasimhan brings a background that's less common in AI governance circles. As a physician-scientist, he oversaw the development and regulatory approval of more than 35 novel medicines at Novartis. Earlier in his career, he worked on HIV/AIDS, malaria, and tuberculosis programs across India, Africa, and South America. He's an elected member of the US National Academy of Medicine and sits on the boards of the University of Chicago and Harvard Medical School.
The parallel to pharma isn't accidental. Drug development requires navigating the tension between moving fast on potentially life-saving treatments and avoiding harm at a population level - a version of the same tradeoff that occupies AI safety researchers. Anthropic, the company behind Claude, has consistently argued that safety and commercial success aren't at odds, and the LTBT is the structural mechanism meant to enforce that.
Narasimhan said in Anthropic's announcement: "Anthropic is setting the standard for how AI should be developed to benefit humanity." Whether that reflects genuine conviction or standard board-appointment language, his record of shepherding complex science through regulatory scrutiny adds credibility to the trust's roster.